North Carolina Construction News staff writer
Genentech, a global leader in biotechnology and a member of the Roche Group, announced plans to invest $700 million in a new manufacturing facility in Holly Springs, creating more than 1,500 construction jobs. When completed, the project will create 400 new jobs and significantly expand North Carolina’s growing life sciences industry.
The facility is intended to support Roche and Genentech’s portfolio of next-generation obesity medicines.
A 700,000-square-foot facility will house a high-volume fill-finish operation to support Genentech’s current product portfolio and future pipeline. The site is the company’s first manufacturing presence on the East Coast and will play a key role in meeting global demand for its medicines.
Based in San Francisco, Genentech has been a pioneer in biotechnology for over four decades, developing treatments for serious and life-threatening diseases. The Holly Springs project marks a major step in expanding its U.S. manufacturing footprint.
“Our new facility near Raleigh, NC, an established biopharmaceutical talent hub, will serve as an important new setting within our manufacturing network to help deliver on the promise of our company’s life-changing science and industry-leading pipeline,” Genentech CEO Ashley Magargee said in a May 12 press release. “We are thrilled to establish this relationship with the city of Holly Springs, where we expect to have a positive impact on the local economy and community, as we have across the United States since we pioneered the biotech industry nearly 50 years ago.”
Local and state officials praised the project as a major win for the region and a reflection of North Carolina’s robust workforce, infrastructure, and biotech ecosystem.